Hepatitis-B as a prognostic discriminant in patients with primary liver cancer.
The prognostic significance of positive serologic determination of hepatitis-B was investigated in 137 patients with primary liver cancer seen over a 6-year period in Pretoria. The median survival time of the 137 patients was 93 days. Patients who were anicteric had a longer survival. Patients who showed positive results for hepatitis-B surface antigen (HBsAg) had a median survival time of 135 days, (39 patients) whereas patients who were HBsAg-negative had a median survival time of 96 days (66 patients). In 57 patients, one or more of the serologic determinations, HBsAg, HBeAg, anti-HBs, anti-HBe, and/or anti-HBc, were positive. Their median survival was 118 days. When HBsAg positivity (or negativity) is corrected for bilirubin, the median survival time remains a function of the bilirubin.
G
G
Falkson
R H
RH
Böhmer
M
M
Adam
B J
BJ
Coetzer
D000328:Adult; D000367:Age Factors; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001663:Bilirubin / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000150:complications*; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000382:microbiology / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D000509:alpha-Fetoproteins / Q000032:analysis; D005719:gamma-Globulins / Q000032:analysis
D006514:Hepatitis B Surface Antigens; D000509:alpha-Fetoproteins; D005719:gamma-Globulins; D000469:Alkaline Phosphatase; D001663:Bilirubin